Effect of Two Intensive Statin Regimens on Progression of Coronary Disease
Effect of Two Intensive Statin Regimens on Progression of Coronary Disease
复制标题
DOI：
10.1056/nejmoa1110874
复制
发表时间：
2011-12-01
影响因子：
158.5
通讯作者：
Nissen, Steven E.
中科院分区：
文献类型：
--
作者：
Nicholls, Stephen J.;Ballantyne, Christie M.;Nissen, Steven E.
背景：他汀类药物降低低密度脂蛋白（LDL）胆固醇的能力与减少心血管不良结局和减缓冠状动脉粥样硬化进展成正比。然而，很少有研究评估强化他汀类药物治疗实现疾病消退的能力，或比较最大他汀类药物治疗的替代方法。方法：我们对1039例冠心病患者进行了连续的血管内超声检查，分别在基线和接受阿托伐他汀（每日80 mg）或瑞舒伐他汀（每日40 mg）治疗104周后，比较这两种强化他汀治疗方案对冠状动脉粥样硬化进展的影响，并评估其安全性和副作用。结果治疗104周后，瑞舒伐他汀组低密度脂蛋白胆固醇水平低于阿托伐他汀组(62.6 vs 70.2 mg / dl [1.62 vs 1.82 mmol / l]， P
BackgroundStatins reduce adverse cardiovascular outcomes and slow the progression of coronary atherosclerosis in proportion to their ability to reduce low-density lipoprotein (LDL) cholesterol. However, few studies have either assessed the ability of intensive statin treatments to achieve disease regression or compared alternative approaches to maximal statin administration.MethodsWe performed serial intravascular ultrasonography in 1039 patients with coronary disease, at baseline and after 104 weeks of treatment with either atorvastatin, 80 mg daily, or rosuvastatin, 40 mg daily, to compare the effect of these two intensive statin regimens on the progression of coronary atherosclerosis, as well as to assess their safety and side-effect profiles.ResultsAfter 104 weeks of therapy, the rosuvastatin group had lower levels of LDL cholesterol than the atorvastatin group (62.6 vs. 70.2 mg per deciliter [1.62 vs. 1.82 mmol per liter], P